Related Experiment Videos
Marizomib for central nervous system-multiple myeloma
Ashraf Badros1, Zeba Singh1, Binod Dhakal2
1M&S Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, MD, USA.
British Journal of Haematology
|April 8, 2017
Summary
Marizomib shows promise for treating central nervous system-multiple myeloma (CNS-MM), a rare cancer complication. These case studies suggest marizomib may be a viable therapeutic option for patients with CNS-MM.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Central nervous system-multiple myeloma (CNS-MM) is a rare, aggressive complication of multiple myeloma with limited treatment options.
- Marizomib, a marine-derived proteasome inhibitor, has shown activity in relapsed-refractory multiple myeloma (RRMM) and malignant glioma.
- There is a significant unmet need for effective therapies targeting CNS-MM.